Literature DB >> 31756246

Invasive Mold Infections After Chimeric Antigen Receptor-Modified T-Cell Therapy: A Case Series, Review of the Literature, and Implications for Prophylaxis.

Ghady Haidar1,2, Kathleen Dorritie1,3, Rafic Farah3, Tatiana Bogdanovich2, M Hong Nguyen1,2, Palash Samanta2.   

Abstract

Data on invasive mold infections (IMIs) after chimeric antigen receptor-modified T-cell (CAR-T-cell) therapy are limited. We describe 2 patients with post-CAR-T-cell IMI (Fusarium, Mucorales) and review the published literature. We propose strategies to prevent IMIs in patients, based on the IMI rate and presence of neutropenia or steroid use.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  CAR-T-cell; fungal infections; neutropenia; prophylaxis; steroids

Year:  2020        PMID： 31756246     DOI： 10.1093/cid/ciz1127

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  15 in total

1.  Chimeric Antigen Receptor T-cell Immunotherapy and Need for Prophylaxis for Invasive Mold Infections.

Authors:  Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2020-10-23       Impact factor: 9.079

Review 2.  How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies.

Authors:  Joshua A Hill; Susan K Seo
Journal:  Blood       Date:  2020-08-20       Impact factor: 22.113

Review 3.  Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy.

Authors:  Kitsada Wudhikarn; Miguel-Angel Perales
Journal:  Bone Marrow Transplant       Date:  2022-07-15       Impact factor: 5.174

Review 4.  Clinical Perspective: Treatment of Aggressive B Cell Lymphomas with FDA-Approved CAR-T Cell Therapies.

Authors:  Mark B Leick; Marcela V Maus; Matthew J Frigault
Journal:  Mol Ther       Date:  2020-10-31       Impact factor: 11.454

5.  Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy - a case report.

Authors:  Kai Rejeski; Wolfgang G Kunz; Martina Rudelius; Veit Bücklein; Viktoria Blumenberg; Christian Schmidt; Philipp Karschnia; Florian Schöberl; Konstantin Dimitriadis; Louisa von Baumgarten; Joachim Stemmler; Oliver Weigert; Martin Dreyling; Michael von Bergwelt-Baildon; Marion Subklewe
Journal:  BMC Infect Dis       Date:  2021-01-28       Impact factor: 3.090

6.  Fungal Infections Associated With the Use of Novel Immunotherapeutic Agents.

Authors:  Marilia Bernardes; Tobias M Hohl
Journal:  Curr Clin Microbiol Rep       Date:  2020-09-26

7.  CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.

Authors:  Kai Rejeski; Ariel Perez; Pierre Sesques; Eva Hoster; Carolina Berger; Liv Jentzsch; Dimitrios Mougiakakos; Lisa Frölich; Josephine Ackermann; Veit Bücklein; Viktoria Blumenberg; Christian Schmidt; Laurent Jallades; Boris Fehse; Christoph Faul; Philipp Karschnia; Oliver Weigert; Martin Dreyling; Frederick L Locke; Michael von Bergwelt-Baildon; Andreas Mackensen; Wolfgang Bethge; Francis Ayuk; Emmanuel Bachy; Gilles Salles; Michael D Jain; Marion Subklewe
Journal:  Blood       Date:  2021-12-16       Impact factor: 22.113

Review 8.  Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic.

Authors:  Veronika Bachanova; Michael R Bishop; Parastoo Dahi; Bhagirathbhai Dholaria; Stephan A Grupp; Brandon Hayes-Lattin; Murali Janakiram; Richard T Maziarz; Joseph P McGuirk; Loretta J Nastoupil; Olalekan O Oluwole; Miguel-Angel Perales; David L Porter; Peter A Riedell
Journal:  Biol Blood Marrow Transplant       Date:  2020-04-14       Impact factor: 5.742

9.  Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-cell Malignancies.

Authors:  Feng Zhu; Guoqing Wei; Yandan Liu; Houli Zhou; Wenjun Wu; Luxin Yang; He Huang; Yongxian Hu
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

Review 10.  Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper.

Authors:  Ibai Los-Arcos; Gloria Iacoboni; Manuela Aguilar-Guisado; Laia Alsina-Manrique; Cristina Díaz de Heredia; Claudia Fortuny-Guasch; Irene García-Cadenas; Carolina García-Vidal; Marta González-Vicent; Rafael Hernani; Mi Kwon; Marina Machado; Xavier Martínez-Gómez; Valentín Ortiz Maldonado; Carolina Pinto Pla; José Luis Piñana; Virginia Pomar; Juan Luis Reguera-Ortega; Miguel Salavert; Pere Soler-Palacín; Lourdes Vázquez-López; Pere Barba; Isabel Ruiz-Camps
Journal:  Infection       Date:  2020-09-26       Impact factor: 7.455
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.